Format

Send to

Choose Destination
World J Urol. 2017 Jul;35(7):1073-1080. doi: 10.1007/s00345-016-1968-2. Epub 2016 Nov 9.

Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study.

Author information

1
Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
2
Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy.
3
Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.
4
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
5
Department of Urology, University of Rennes, Rennes, France.
6
Department of Urology, Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris, France.
7
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
8
Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
9
Department of Pathology, Medical University of Vienna, Vienna, Austria.
10
Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. sfshariat@gmail.com.
11
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. sfshariat@gmail.com.
12
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. sfshariat@gmail.com.
13
Department of Urology, Weill Cornell Medical College, New York, NY, USA. sfshariat@gmail.com.

Abstract

PURPOSE:

To assess the role of N-cadherin as prognostic biomarker in patients with upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients.

PATIENTS AND METHODS:

Immunohistochemistry was used to evaluate the status of N-cadherin expression in 678 patients with unilateral sporadic UTUC treated with radical nephroureterectomy. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected. The Kaplan-Meier method was used to estimate recurrence-free survival, overall survival and cancer-specific survival. Disease recurrence, overall mortality and cancer-specific mortality probabilities were tested in Cox regression models.

RESULTS:

Expression of N-cadherin was observed in 292 (43.1%) of patients, and it was associated with advanced tumour stage (p < 0.04), lymph node metastases (p = 0.04) and sessile architecture (p < 0.02). Within a median follow-up of 37.5 months (IQR 20-66), 171 patients (25.2%) experienced disease recurrence and 150 (22.1%) died from UTUC. In univariable analyses, N-cadherin expression was significantly associated with higher probability of recurrence (p = 0.01), but not overall (p = 0.9) or cancer-specific mortality (p = 0.06). When adjusted for the effects of all available confounders, N-cadherin was not associated with any of the survival outcomes.

CONCLUSION:

N-cadherin is expressed in approximately 2/5 of UTUs. It is associated with adverse pathologic factors but not with survival outcomes. Its clinical value remains limited.

KEYWORDS:

N-Cadherin; Prediction; Survival; UTUC prognosis; Upper tract urothelial carcinoma; Urothelial carcinoma

PMID:
27830374
PMCID:
PMC5486535
DOI:
10.1007/s00345-016-1968-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center